Migraine is a chronic medical condition affecting an estimated 38 million people in the United States. Throbbing, often one-sided moderate-to-severe head pain, accompanied by light and sound sensitivity and nausea/vomiting are the most common symptoms. Some migraine sufferers experience dizziness, visual symptoms, numbness or weakness on one side of the body, slowed thinking or trouble speaking.
Migraine predominantly effects young and middle-aged woman (that is, during their prime work and child-rearing years), though it can strike men and children as well. When untreated, the World Health Organization lists migraine as among the top ten most disabling medical conditions.
Our migraine research program aims to find better acute and preventive treatments for adults and children who suffer from migraine. Our current and upcoming studies include:
- The first option is an oral CGRP medicine for acute treatment of migraine. By now most migraine sufferers have heard of CGRP (the inflammatory molecule in the brain that triggers a migraine), since several CGRP-blocking shots have come to market. This is a CGRP-blocker in a pill form. You may qualify for this study (in which you’ll get either the CGRP-blocker or a placebo pill) if you have 2-14 migraines a month. This study is a quick and easy, single dose study that only requires three office visits. Learn More
- Another trial we have for those who don’t like pills or shots, is a trial that is testing a device for medication delivery. In this trial, the device uses a small catheter placed deep in the nose to instill a tiny spray of medicine onto the SPG, a pain nerve that sits between the nose and brain. This study is for those with Chronic Migraine (15 or more headache days per month). Learn More
- The next study is not about a pharmaceutical, but rather a hand-held device that is placed on the side of the neck, adjacent to the windpipe, for 2-3 minutes. The device stimulates the vagus nerve, which is an important nerve for pain processing in the brain. The device has already been approved and is available for acute treatment of migraine and cluster headache. This study examines the device’s utility as a daily migraine preventive therapy. Subjects will receive either the real device or a non-active “dummy” device. Learn More
- This trial is another CGRP-blocking pill, this time for daily use as a migraine prevention agent. Like nearly all research studies, participants will receive either the medication or a sugar pill for the double-blind phase. This study comes with an Open Label phase, which is where everyone gets the real drug for the remaining time in the study. Learn More
All studies at NEICR are available at no cost to you, and there may be compensation for time and travel. Participation is completely voluntary, and you may withdraw at any time. To find out more about any of our studies, give us a call at 203-914-1903 or fill out the form below.